Medical Industry Feature

Try it Now Firm without compromise. Cancel whenever you want.

Synopsis

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Episodes

  • Unexplained Hematologic Abnormalities: Could It Be Type 1 Gaucher Disease?

    Unexplained Hematologic Abnormalities: Could It Be Type 1 Gaucher Disease?

    19/05/2020

    Host: Matt Birnholz, MD Guest: Joel Weinthal, MD Type 1 Gaucher disease is a progressive and lifelong genetic disease, and when the diagnosis is missed, this can lead to some serious implications or consequences. And since hematologists-oncologists play a pivotal role in identifying and diagnosing these patients, Dr. Matt Birnholz speaks with Dr. Joel Weinthal, Medical Director at Medical City Hospital, about the symptoms of Gaucher disease hematologists-oncologists should look for, how to test and diagnose, the consequences of diagnostic delays, and more. MAT-US-2003112 5/2020

  • Nutrition in the ICU: The Power of Protein in Critically Ill Patients

    Nutrition in the ICU: The Power of Protein in Critically Ill Patients

    12/05/2020

    Guest: Juan Ochoa, MD Join Dr. Juan Ochoa, Medical Director of Surgical Intensive Care at Oschsner Medical Center, as he reviews a retrospective study that investigated the impacts of high-protein, low-calorie feedings on critically ill patients in the ICU. Dr. Ochoa is a Surgeon, physician scientist, and former Chief Medical Officer of Nestlé Health Science.

  • What Bit Him: An Expert Perspective on Snake Antivenom

    What Bit Him: An Expert Perspective on Snake Antivenom

    27/04/2020

    Guest: Mark Ryan, PharmD The more time that passes before a snake bite is treated, the higher the risk of long-term or even permanent morbidity due to tissue damage. So when time is tissue, why risk it? Join Dr. Mark Ryan from the Louisiana Poison Control Center as he shares important information on the antivenom CroFab®, including its development, how it quickly controls envenomation effects, and its demonstrated safety profile.

  • Navigating the Snake Bite Treatment Algorithm

    Navigating the Snake Bite Treatment Algorithm

    27/04/2020

    Guest: Spencer Greene, MD, MS, FACEP, FACMT, FAAEM The Unified Treatment Algorithm is a consensus guideline prepared by a panel of experts that provides a simple, step-by-step guide on assessing and treating a patient who’s been bitten by a pit viper. Knowing the correct treatment approach is just as important as understanding what not to do, as Dr. Spencer Greene explains.

  • The 3 Critical Aspects of Snake Bite Management

    The 3 Critical Aspects of Snake Bite Management

    27/04/2020

    Guest: William Banner, MD, PhD Tissue damage caused by North American pit viper envenomation occurs quickly in snake bite victims. Join Dr. Bill Banner as he discusses three critical aspects of snake bite management and how treatment with CroFab® can be a viable option for patients.

  • Multiple Sclerosis  Aging: Considerations for Diagnosis  Treatment

    Multiple Sclerosis & Aging: Considerations for Diagnosis & Treatment

    23/04/2020

    Host: Jennifer Caudle, DO Guest: Riley Bove, MD Guest: Bianca Weinstock-Guttman, MD The disease course of multiple sclerosis (MS) can take many paths based on numerous factors, including age at diagnosis, gender, and MS subtype. Layered upon the typical MS management challenges are those that can occur with the physical and physiological changes of the normal aging process. How might the care of a patient with MS need to be modified as they age? In this discussion, Dr. Bove and Dr. Weinstock-Guttman will review: The effects that aging may have on patients with MS The interplay between menopause and MS How aging may affect the approach to disease management EMD Serono is a business of Merck KGaA, Darmstadt, Germany. ©EMD Serono, Inc. All rights reserved. US/NPR/1019/0520B

  • Insights on an IBS-D Therapy that Can Help Relieve Symptoms

    Insights on an IBS-D Therapy that Can Help Relieve Symptoms

    20/04/2020

    Guest: Gregory S. Sayuk, MD, MPH Please click here for full Prescribing Information. Irritable bowel syndrome with diarrhea can have a significant impact on patients’ daily activities due to debilitating symptoms like abdominal pain and diarrhea, both of which could be a result of alterations in the gut microbiota. Joining us to discuss XIFAXAN (rifaximin), the only FDA-approved treatment that alters the gut microbiota in IBS-D, is Dr. Gregory Sayuk.

  • Exploring the Underdiagnosis of AS Within  Around Rheumatology Practices

    Exploring the Underdiagnosis of AS Within & Around Rheumatology Practices

    08/04/2020

    Host: Matt Birnholz, MD Guest: Sanjay Chabra, MD As stated by Dr. Sanjay Chabra, "About 19 percent of the population lives with chronic back pain, but what about when it’s inflammatory—not mechanical—back pain?" Join Dr. Matt Birnholz as he sits down with Dr. Chabra at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to share strategies that can help us shorten the delay in the diagnosis of ankylosing spondylitis that often occurs within and around rheumatology practices. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

  • Uncovering Hidden Clues in Diagnosing Psoriatic Arthritis

    Uncovering Hidden Clues in Diagnosing Psoriatic Arthritis

    08/04/2020

    Host: Matt Birnholz, MD Guest: Roger Kornu, MD To help address the gap in awareness across the field regarding the development of psoriatic arthritis, Dr. Roger Kornu joins Dr. Matt Birnholz at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to discuss commonly overlooked symptoms, including plaque psoriasis, dactylitis, and enthesitis. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

  • Dietary Understandings  Updates for Rheumatoid Arthritis Patients

    Dietary Understandings & Updates for Rheumatoid Arthritis Patients

    17/03/2020

    Host: Matt Birnholz, MD Guest: Smitha Reddy, MD Join Dr. Matt Birnholz as he sits down with Dr. Smitha Reddy at the annual rheumatology meeting in Atlanta, Georgia to explore how an anti-inflammatory diet could have an impact on a rheumatoid arthritis patient's lifestyle. PP-BA-US-1149 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

  • Early Signs  Symptoms of Rheumatoid Arthritis

    Early Signs & Symptoms of Rheumatoid Arthritis

    17/03/2020

    Host: Matt Birnholz, MD Guest: Ara Dikranian, MD Did you know joint stiffness and tenderness as well as joint pain could be early signs and symptoms of rheumatoid arthritis? Once symptoms are identified, how do you know which patients should be referred to a rheumatologist? Answering those and other questions is Dr. Ara Dikranian, who sat down with Dr. Matt Birnholz at the annual rheumatology meeting in Atlanta, Georgia. PP-BA-US-1143 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

  • Making a Difference for Patients with sHPT

    Making a Difference for Patients with sHPT

    16/03/2020

    Host: John J. Russell, MD Guest: David Henner, DO Guest: Abdul Abdellatif, MD, FASN With the ever-increasing pace and pressures faced by nephrology professionals both in the office and at the dialysis center, how can you keep up? John Russell, MD welcomes two community nephrologists, David Henner, DO from Pittsfield, Massachusetts, and Adbul Abdellatif, MD, FASN from Houston, Texas, to talk about just that. Together, they explore how nephrologists are dealing with the changing landscape of nephrology and how a drug called Parsabiv® is playing a role in the important work they do. This promotional, non-CME program is intended for US Health Care Professionals. David Henner, DO and Adbul Abdellatif, MD, FASN were paid a fee by Amgen for their participation in the program.

  • Dosing Practices in sHPT

    Dosing Practices in sHPT

    16/03/2020

    Host: John J. Russell, MD Guest: Abdul Abdellatif, MD, FASN Guest: Debbie Glidden, MSN, APRN-BC, CNN How can you control the administration of calcimimetics for your patients with chronic kidney disease who are on hemodialysis and suffering from secondary hyperparathyroidism, also known as sHPT? John Russell, MD sits down with two community nephrology professionals, Adbul Abdellatif, MD, FASN from Houston, Texas, and Debbie Glidden, MSN, APRN-BC, CNN from Orlando, Florida. They will be discussing a dosing practice involving oral cinacalcet and what alternatives they suggest for nephrologists who are concerned about controlling the administration of sHPT treatment in an approved fashion. This promotional, non-CME program is intended for US Health Care Professionals. Adbul Abdellatif, MD, FASN and Debbie Glidden, MSN, APRN-BC, CNN were paid a fee by Amgen for their participation in the program.

  • A Closer Look at an IV-Administered Treatment Option for sHPT

    A Closer Look at an IV-Administered Treatment Option for sHPT

    16/03/2020

    Host: John J. Russell, MD Guest: Debbie Glidden, MSN, APRN-BC, CNN Guest: David Henner, DO When your patients with chronic kidney disease who are on hemodialysis are suffering from secondary hyperparathyroidism, also known as sHPT, what can you do? John Russell, MD sits down with two community nephrology professionals, David Henner, DO from Pittsfield, Massachusetts, and Debbie Glidden, MSN, APRN-BC, CNN from Orlando, Florida, to discuss just that. Learn what these clinicians did to treat sHPT before Parsabiv®, and how the arrival of Parsabiv® changed things for them, their practices, and their patients. This promotional, non-CME program is intended for US Health Care Professionals. David Henner, DO and Debbie Glidden, MSN, APRN-BC, CNN were paid a fee by Amgen for their participation in the program.

  • All Elevations Are True Elevations with High-Sensitivity Troponin T

    All Elevations Are True Elevations with High-Sensitivity Troponin T

    13/03/2020

    Host: Jennifer Caudle, DO Guest: Lori Daniels, MD The benefits of high-sensitive troponin expands beyond the Emergency Department to Cardiology. When used in conjunction with clinical findings, high-sensitive troponins can enable earlier diagnosis of myocardial infarction, more confident dispositions, and improved patient satisfaction than conventional troponins. Joining Dr Jennifer Caudle is Dr Lori Daniels, Director of the Cardiovascular Intensive Care Unit and the University of California in San Diego, who discusses the adoption of Elecsys Troponin T Gen 5 in her health system.

  • Elevating the Lab with High-Sensitivity Troponin T

    Elevating the Lab with High-Sensitivity Troponin T

    13/03/2020

    Host: Jennifer Caudle, DO Guest: Ibrahim A Hashim, PhD Providing healthcare practitioners with nearly 75 percent of the patient data needed to make a clinical decision, the laboratory can be a valuable partner in improving quality measures and evaluating novel biomarkers throughout a hospital or health system. Joining Dr Jennifer Caudle is Dr Ibrahim Hashim, Professor and Chief of Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas Texas, who discusses how the lab played a pivotal role in the adoption of Elecsys Troponin T Gen 5 at Parkland Memorial Hospital.

  • Easing the Emergency Department Pressure with High-Sensitivity Troponin T

    Easing the Emergency Department Pressure with High-Sensitivity Troponin T

    13/03/2020

    Host: Jennifer Caudle, DO Guest: Christopher Baugh, MD, MBA Although 6 million patients visit the Emergency Department every year with chest pain symptoms1, less than 4 percent of those visits lead to a diagnosis of acute myocardial infarction2. To address this gap, Dr. Jennifer Caudle is joined by Dr. Christopher Baugh, Vice Chair of Clinical Affairs at Brigham and Women's Hospital and Associate Professor at Harvard Medical School in Boston Massachusetts, who discusses the adoption of Elecsys Troponin T Gen 5 across the system's Emergency Departments. References U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics, https://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2013_ed_web_tables.pdf (accessed February 27, 2020). Hsia, R.Y., Z. Hale and J.A. Tabas. (2016). A National Study of the Prevalence of Life-Threatening Diagnoses in Patients with Chest Pain. JAMA Internal Medicine 176(7):1029–1032.

  • Jason Day’s Ultimate Drive: Helping His Mom Fight Lung Cancer

    Jason Day’s Ultimate Drive: Helping His Mom Fight Lung Cancer

    05/03/2020

    Guest: Jason Day Guest: Dening Day Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3 In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results. Share this video and more with your patients by visiting TestLungCancer.com. References: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding

  • Rapid Initiation: Getting Newly Diagnosed HIV-1 Patients on ARV Treatment Quickly

    Rapid Initiation: Getting Newly Diagnosed HIV-1 Patients on ARV Treatment Quickly

    03/02/2020

    Host: Jennifer Caudle, DO Guest: Moti Ramgopal, MD As a healthcare provider, it can be important to minimize the time between diagnosis and the beginning of therapy for newly diagnosed HIV-1 patients. That’s why infectious disease specialist Dr. Moti Ramgopal explains how SYMTUZA® can help us close the gap between those two crucial points of a HIV-1 care and be a treatment option when rapididly initiating patients. INDICATION SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. IMPORTANT SAFETY INFORMATION BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coi

  • Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

    Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

    13/01/2020

    Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

page 1 from 3

Informações: